PHOENIX, AZ--(Marketwired - May 07, 2013) - Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced the closing of its initial public offering. The company also announced that the underwriters exercised their full over-allotment option to purchase an additional 600,000 shares at the offering price of $8.00 per share. With the exercise of the over-allotment option, the total number of shares sold in the offering was 4,600,000 shares, resulting in aggregate gross proceeds of $36.8 million, before underwriting discounts, commissions and expenses. All of the shares were offered by Insys Therapeutics.
Wells Fargo Securities, LLC and JMP Securities LLC acted as joint book-running managers for the offering. Oppenheimer & Co. acted as co-manager.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A registration statement relating to the offering has been filed with, and declared effective by, the Securities and Exchange Commission. The offering is being made only by means of a final prospectus, which is part of the effective registration statement. Copies of the final prospectus may be obtained by contacting Wells Fargo Securities, LLC, 1525 West W.T. Harris Boulevard, NC0675, Charlotte, NC 28262, Attn: Capital Markets Client Support, telephone: 1-800-326-5897 or email: email@example.com; or JMP Securities LLC, Attn: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111 (415-835-8985).
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. We have two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. We market Subsys through our incentive-based, cost-efficient commercial organization of approximately 67 sales professionals. Our lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be our second branded supportive care product, if approved.